Report Overview

The global thrombin market was pegged at US$ 570 million in 2021 and is expected to witness a CAGR of 3.80% during the forecast period.

Market Fundamentals

A protease enzyme produced from prothrombin helps in creating blood clot by catalyzing the conversion of fibrinogen into fibrin. Thrombin is an unusual molecule that performs both procoagulant and anticoagulant actions. Through the platelets receptor, it activates platelets in its procoagulant function. Through the activation of coagulation factors V, VIII, and even XI, it controls the production of thrombin. Thrombin is used in coagulation cascade, also it is used as clotting factor. Additionally, thrombin is used in production of prothrombin, and in production of antibodies against thrombin. Moreover, in order to avoid disseminated intravascular coagulation (DIC) and fatalities during operations, thrombin is used in close proximity to bigger vessels.

[3632864]

Market Dynamics

The primary drivers propelling the global thrombin market are increased prevalence of blood clotting disorder, increased rate of obesity and trending lifestyle shifts such as excessive smoking. Additionally, market players are also focusing on development of medicinal thrombin effects. However, delay in the production and supply chain of recombinant human thrombin is a restraining factor for thrombin market. 

Market Ecosystem

The global thrombin market has been analyzed from four perspectives: by product, by dosage form, by end user, and by region. 

Thrombin Market by Product

[1232434]

On the basis of product types, the global thrombin market is segmented into human thrombin, bovine thrombin, and recombinant thrombin. The bovine sourced thrombin has shown the highest growth, as it is most frequently used product due to its affordable prices; the segment is anticipated to continue to dominate the market during the projected period. The market is also being influenced by the increasing use of bovine-based products in different research and diagnostic applications. Additionally, high demand of topical bovine thrombin (THROMBIN-JMI) is recommended to help hemostasis when bleeding from capillaries and small venules is visible and cannot be controlled by standard surgical methods (such as suture, ligature, or cautery). The potential for contamination in animal-based thrombin, other segments such as human-based thrombin are also anticipated to demonstrate high growth during the projected period. Additionally, human thrombin benefits from having low levels of antigenicity and no risk of viral transmission. Thrombin is frequently combined with other hemostatic agents, such as absorbable substances like Gelfoam and fibrinogen in fibrin glues, to provide hemostasis.

Thrombin market by Dosage Form 

Based on dosage form, the global thrombin market is grouped into solution form, and powder form. The solution form has shown high growth due to its high adoption by physicians, it is clinically effective, and are more stable than powder form. The powder segment is also anticipated to grow in the forecast period due to high recommendation of THROMBIN-JMI, manufactured by Pfizer. This is a bovine based thrombin which is manufactured as a sterile powder that has been freeze-dried. Additionally, the powder form is much more stable as compared to solution form thrombin. 

Thrombin market by Region 

Geographically, the global thrombin market is grouped into North America, Europe, Asia Pacific, and the Rest of the World. Throughout the forecast period, North America is anticipated to lead the market. The presence of significant market players, high frequency of accidents and trauma in the region, and the rise in the incidence of inherited blood disorders are all contributing factors to the market expansion. Major section of market share can be attributed to well-established healthcare infrastructure. In addition, encouraging government initiatives and a rise in research collaboration numbers are among the factors anticipated to boost market expansion. Due to its pro-patient legislations, large patient population, and developed healthcare market, the United States has the largest share in North America. The European region is growing steadily due to high incidence of blood clotting disorders, and drug manufacturers having high interest in drug development. The Asia Pacific region is anticipated to show high growth in the forecast period due to early availability of novel technologies, high awareness, large health care spending in overall national budgets, and extensive research activity in this region. 

Competitive Landscape

Some of the prominent players operating in the thrombin market are 

• Bayer AG
• Takeda Pharmaceutical Company     
• Pfizer Inc. 
• GE Healthcare Systems 
• Johnson and Johnson Services Inc. 
• Baxter International Inc. 
• Octapharma AG
• Grifols S.A.
• Omrix Biopharmaceuticals, Inc. 
• Hualan Biological Engineering Inc. 

Frequently Asked Questions About This Report